EGM
LYEL icon

Engineers Gate Manager’s Lyell Immunopharma LYEL Stock Holding History

Engineers Gate Manager’s Portfolio LYEL Stock Details LYEL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-735
Closed -$114K – 2127
2021
Q4 		$114K Buy
+735
New +$164K 0.01% 1789

Other funds holding LYEL

MM
MWG Management Road Town, Tortola, British Virgin Islands $81.3M AUM 2.28% 1-Year Est. Return
A
Apoletto Road Town, Tortola, British Virgin Islands $260M AUM 31.4% 1-Year Est. Return
FCMI
Foresite Capital Management IV Larkspur, California $237M AUM 107.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
HH
HSG Holding Na, Hong Kong $1.62B AUM 5.91% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Engineers Gate Manager's LYEL Position: Q1 2022 in Review

Engineers Gate Manager sold out of Lyell Immunopharma (LYEL) in Q1 2022, closing a stake of 735 shares — an estimated $114K sold.

Engineers Gate Manager first reported a position in LYEL in Q4 2021 and held it in 1 quarter. The position peaked at $114K in Q4 2021. 79 funds tracked by Wall St. Rank hold LYEL as of Q1 2022.

  • Engineers Gate Manager reported no remaining Lyell Immunopharma position as of Q1 2022 after selling out during the quarter.
  • Engineers Gate Manager sold 735 Lyell Immunopharma shares in Q1 2022, an estimated $114K.
  • Engineers Gate Manager first reported a position in Lyell Immunopharma in Q4 2021 and held it in 1 quarter.
  • Engineers Gate Manager's Lyell Immunopharma position peaked at $114K in Q4 2021.
  • 79 funds tracked by Wall St. Rank held Lyell Immunopharma as of Q1 2022.

Based on Engineers Gate Manager's 13F filing for Q1 2022, filed 16 May 2022.